2025年度影响经营业绩的主要因素：报告期内，因主要产品价格及销售策略的调整以及持续的高比例研 发投入，对公司营业收入和利润产生阶段性影响。 格隆汇2月27日丨悦康药业(688658.SH)公布2025年度业绩快报，2025年度公司实现营业总收入24.46亿 元，较上年同期下降35.30%；实现归属于母公司所有者的净利润-2.54亿元，较上年同期下降305.18%。 实现归属于母公司所有者的扣除非经常性损益的净利润-2.8亿元，较上年同期下降352.83%。 ...

证券日报网讯 2月27日，悦康药业发布2025年度业绩快报公告称，公司2025年度实现营业总收入 244608.70万元，同比下降35.30%；归属于母公司所有者的净利润为-25383.67万元。 （文章来源：证券日报） ...

Core Viewpoint - Yuyuan Pharmaceutical reported a significant decline in revenue and net loss for the year 2025, indicating challenges in its business performance and strategic adjustments in product pricing and sales [1] Financial Performance - The company achieved total operating revenue of 2.446 billion yuan in 2025, a year-on-year decrease of 35.3% [1] - The net loss attributable to the parent company was 254 million yuan, representing a year-on-year increase of 305.18% [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, was 280 million yuan, reflecting a year-on-year increase of 352.83% [1] Strategic Adjustments - At the end of 2024, the company adjusted the pricing and sales strategy for its product "Ginkgo Biloba Extract Injection," which had a significant impact on revenue and profit [1] - The increase in research and development expenses during the reporting period also contributed to the negative impact on net profit [1]

证券代码：688658 证券简称：悦康药业 公告编号：2026-007 悦康药业集团股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以悦康药业集团股份有限公司（以下简称"公司"）2025年年度报告为准， 提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 注：1.本报告期初数同法定披露的上年年末数。 2.以上数据及指标为合并报表数据，但未经审计，最终结果以 2025 年年度报告为准。 3.以上增减变动幅度数据如有尾差，是由四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 2025 年度公司实现营业总收入 244,608.70 万元，较上年同期下降 35.30%； 实现营业利润-22,538.70 万元，较上年同期下降 241.70%。实现归属于母公司所 有者的净利润-25,383.67 万元，较上年同 ...

悦康药业发布业绩快报，2025年度公司实现营业总收入24.46亿元，较上年同期下降35.30%；实现营业 利润-2.25亿元，较上年同期下降241.70%。实现归属于母公司所有者的净利润-2.54亿元，较上年同期下 降305.18%。实现归属于母公司所有者的扣除非经常性损益的净利润-2.8亿元，较上年同期下降 352.83%。 ...

Group 1 - Beixin Road and Bridge won a bid for a project worth 751 million yuan [1] - Beijing Keri won bids for projects totaling approximately 588 million yuan [2] - Saifu Tian's subsidiary Anhui Meidalen resumed production after maintenance [3] Group 2 - ST Songfa's subsidiary signed contracts for the construction of three ultra-large oil tankers, with a total contract value of approximately 300 to 400 million USD [4] - Kanghong Pharmaceutical received clinical trial approval for KHN707 tablets for insomnia [5] - Koweil reported a 32.32% year-on-year increase in net profit for 2025 [6] Group 3 - Shandong Haohua plans to invest 4.837 billion yuan in a soda ash facility upgrade for energy efficiency and environmental protection [7] - Changsha Bank's president Zhang Man applied for resignation due to job changes [8] - Wens Foodstuff Group plans to repurchase A-shares worth between 800 million and 1.2 billion yuan [9] Group 4 - SMIC's application for issuing shares to purchase assets was accepted by the Shanghai Stock Exchange [10] - Sainuo Medical reported a 14.53% year-on-year increase in revenue for 2025 [11] - Chaohongji opened a new direct store in January [12] Group 5 - Taoli Bread's controlling shareholder plans to reduce holdings by up to 3% [13] - Anglikang's subsidiary received approval for a veterinary drug product [14] - Tuori New Energy's controlling shareholder plans to reduce holdings by up to 3% [15] Group 6 - Qianyuan Pharmaceutical acquired 20% equity in Qianyuan Hailisheng for 77.36 million yuan [16] - Zhaobiao Co. shareholders plan to reduce holdings by up to 3% [17] - Sichuan Gold shareholders plan to reduce holdings by up to 2.119% [18] Group 7 - Longhua New Materials shareholders plan to reduce holdings by up to 1.63% [19][20] - Yutong Technology plans to acquire 60% of Gelbert for approximately 654.37 million euros [21] - ST Xinhua Jin was investigated for information disclosure violations [22] Group 8 - Sanjing Guojian's new drug application for an anti-IL-4Rα monoclonal antibody was accepted [23] - Tianshan Aluminum's controlling shareholders plan to reduce holdings by up to 2% [24] - Baisheng Intelligent's vice chairman plans to reduce holdings by up to 3% [25] Group 9 - Huaxin Environmental Protection's directors and executives plan to reduce holdings by up to 1.4% [26] - Zhongjin Irradiation shareholders plan to reduce holdings by up to 1% [27] - Gree Electric's major shareholder plans to reduce holdings by up to 2% [28] Group 10 - Yuekang Pharmaceutical's controlling shareholder's shares will be auctioned [29] - Hengxuan Technology reported a 27.75% year-on-year increase in net profit for 2025 [30] - Dae Oriental plans to invest 50 million yuan in the Junfu Zhi Cun Fund [31] Group 11 - Tailin Micro's application for issuing shares and raising matching funds was accepted by the Shanghai Stock Exchange [32] - ST Yanshi warned of potential delisting risks due to stock price volatility and financial issues [33] - Bertley plans to acquire a controlling stake in Yubei Turning [34] Group 12 - Whirlpool's subsidiary plans to invest 30 million USD in purchasing shares of Whirlpool Group [35] - Frantac's controlling shareholder is planning a share transfer, leading to a temporary suspension of stock trading [36]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688658 证券简称：悦康药业 公告编号：2026-006 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被司法拍卖的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次司法拍卖的主要内容 （一）拍卖标的：京悦永顺持有的悦康药业172万股股票（证券名称：悦康药业，证券代码：688658， 证券性质：无限售流通股）。 1、拍卖时间：2026年3月16日10时至2026年3月17日10时止（延时除外） 2、拍卖地点：在北京市第二中级人民法院京东网司法拍卖网络平台（网址：http://sifa.jd.com/29户名： 北京市第二中级人民法院）上进行公开拍卖活动。 3、本次拍卖为第一次拍卖，展示起拍价：40,170,600元，保证金：8,000,000元，增价幅度：200,000 元。 特别说明：本次拍卖起拍价以拍卖日前20个交易日股票的收盘价均价乘以172万股的金额乘以90%后作 为本次拍卖起拍价。平台公示价格为展示价格，非 ...

格隆汇2月25日丨悦康药业(688658.SH)公布，公司于近日接到控股股东京悦永顺通知，其持有的悦康药 业172万股股票将在北京市第二中级人民法院（简称"北京二中院"）京东网司法拍卖网络平台进行拍 卖。 ...

证券代码：688658 证券简称：悦康药业 公告编号：2026-006 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被司法拍卖的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"或"悦康药业"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有公司股份 153,740,120 股，占公司总股本的比例为 34.16%。截至本公告披露日，本次京悦 永顺持有的本公司 1,720,000 股无限售流通股股票将被司法拍卖。 （一）拍卖标的：京悦永顺持有的悦康药业 172 万股股票（证券名称：悦康 药业，证券代码：688658，证券性质：无限售流通股）。 1、拍卖时间：2026 年 3 月 16 日 10 时至 2026 年 3 月 17 日 10 时止（延时 除外） 2、拍卖地点：在北京市第二中级人民法院京东网司法拍卖网络平台（网址： http://sifa.jd.com/29 户名：北京市第二中级人民法院）上进行公开拍卖活动。 3、本次 ...

（文章来源：第一财经） 悦康药业公告，控股股东阜阳京悦永顺信息咨询有限公司持有的本公司172万股无限售流通股股票将被 司法拍卖。该事项不会影响公司控制权稳定，亦不会对公司日常经营管理造成影响。 ...